Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

Dysregulated activation of the CDK4/6 kinases is a hallmark of most mammary-derived carcinomas. ATP-competitive inhibitors against this complex have been recently advanced in the clinic and have shown significant activity, particularly against tumors driven by the estrogen receptor (ER). However, re...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2017-04, Vol.36 (16), p.2255-2264
Hauptverfasser:	Yang, C, Li, Z, Bhatt, T, Dickler, M, Giri, D, Scaltriti, M, Baselga, J, Rosen, N, Chandarlapaty, S
Format:	Artikel
Sprache:	eng
Schlagworte:	13/106 13/31 13/51 14/32 38/109 38/23 38/77 631/67/1347 Aminopyridines - pharmacology Apoptosis Benzimidazoles - pharmacology Breast cancer Breast Neoplasms - diet therapy Breast Neoplasms - enzymology Breast Neoplasms - metabolism Cell Biology Cell Line, Tumor Cyclin-Dependent Kinase 4 - antagonists & inhibitors Cyclin-Dependent Kinase 6 - antagonists & inhibitors Cyclin-Dependent Kinase 6 - genetics Drug resistance Drug Resistance, Neoplasm Estrogens Female Gene Amplification Human Genetics Humans Inhibitor drugs Internal Medicine Kinases MCF-7 Cells Medicine Medicine & Public Health Neurons Oncology Original original-article Protein Kinase Inhibitors - pharmacology Receptors, Estrogen - metabolism Signal Transduction - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!